Related Experiment Video
Updated: Jun 30, 2025
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
Isoliquiritigenin reduces experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the
Rui Feng1, Tong Meng1, Xiaohu Zhao1
1Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, PR China; Institute of Urology, Anhui Medical University, Hefei, Anhui, PR China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, Anhui, PR China.
Background:
Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) lead to severe irritation and impaired sperm quality in males. However, current therapeutic options often fail to achieve satisfactory effects. Consequently, the investigation of novel treatment strategies or remedies holds substantial clinical importance. As a flavonoid monomer, isoliquiritigenin (ISL) has been shown to possess anti-inflammatory activity, especially in several chronic nonspecific-inflammatory conditions. Thus, an exploration of the possible anti-inflammatory effects of ISL on CP/CPPS, a chronic aseptic inflammation of the prostate, has significant potential.
Methods:
An experimental autoimmune prostatitis (EAP) model was used for the evaluation of the anti-inflammatory effects of ISL. It was found that ISL treatment could reduce the secretion and invasion of pro-inflammatory cytokines in prostate tissue. In EAP mice, ISL treatment also reduced oxidative stress (OS) and activation of the NLRP3 inflammasome. In vitro, ISL upregulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and inhibited NLRP3 inflammasome activation in RAW264.7 macrophages exposed to lipopolysaccharide (LPS).
Results:
Treatment with ISL treatment relieved prostate inflammation and pelvic pain in EAP mice. Both in vivo and in vitro, ISL treatment activated Nrf2/HO-1 signaling, which in turn inhibited oxidative stress and activation of the NLRP3 inflammasome. Blockade of Nrf2/HO-1 signaling abolished the inhibitory effects of ISL on oxidative stress and NLRP3 inflammasome activation.
Conclusions:
Isoliquiritigenin reduced experimental autoimmune prostatitis by facilitating Nrf2 activation and suppressing the NLRP3 inflammasome pathway.
Insights
Isoliquiritigenin (ISL) effectively reduced prostate inflammation and pelvic pain in a mouse model by activating Nrf2/HO-1 signaling, thereby inhibiting oxidative stress and NLRP3 inflammasome activation. This study highlights ISL as a potential therapeutic for chronic prostatitis.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) cause significant male reproductive health issues.
- Current treatments for CP/CPPS offer limited efficacy, necessitating novel therapeutic strategies.
- Isoliquiritigenin (ISL), a flavonoid, exhibits anti-inflammatory properties relevant to chronic inflammatory conditions.
Purpose of the Study:
- To investigate the anti-inflammatory effects of isoliquiritigenin (ISL) on chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS).
- To explore the underlying molecular mechanisms, including Nrf2 activation and NLRP3 inflammasome inhibition, of ISL's therapeutic potential.
Main Methods:
- An experimental autoimmune prostatitis (EAP) mouse model was utilized to assess ISL's efficacy.
- In vitro studies involved RAW264.7 macrophages stimulated with lipopolysaccharide (LPS) to evaluate ISL's effects on oxidative stress and inflammasome activation.
- Key molecular pathways, including Nrf2/HO-1 signaling and NLRP3 inflammasome activation, were analyzed both in vivo and in vitro.
Main Results:
- ISL treatment significantly alleviated prostate inflammation and pelvic pain in EAP mice.
- ISL demonstrated anti-inflammatory effects by reducing pro-inflammatory cytokine secretion and invasion in prostate tissue.
- Both in vivo and in vitro, ISL activated Nrf2/HO-1 signaling, which suppressed oxidative stress and NLRP3 inflammasome activation.
Conclusions:
- Isoliquiritigenin effectively ameliorates experimental autoimmune prostatitis by activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome.
- The findings suggest that ISL holds promise as a novel therapeutic agent for CP/CPPS.
- Targeting the Nrf2/HO-1 and NLRP3 inflammasome pathways presents a viable strategy for managing chronic prostatitis.
